EpCAM antibody

Catalog No. ABIN2664580

The Mouse Monoclonal anti-EpCAM antibody is suitable to detect EpCAM in samples from Human. It has been validated for FACS.

Quick Overview for EpCAM antibody (ABIN2664580)

Target: EpCAM (EPCAM) (Epithelial Cell Adhesion Molecule (EPCAM))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This EpCAM antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: 9C4

Product Details anti-EpCAM Antibody

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for EpCAM

Target: EpCAM (EPCAM) (Epithelial Cell Adhesion Molecule (EPCAM))

Alternative Name: CD326

Background: CD326 is also known as Ep-CAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma associated antigen, and TROP1. CD326 is a type I transmembrane protein containing six disulfide bridges and one THYRO domain. This cell surface glycosylated 40 kD protein is highly expressed in bone marrow, colon, lung, and most normal epithelial cells and is expressed on carcinomas of gastrointestinal origin. Recently, it has been reported that CD326 expression occurs during the early steps of erythrogenesis. CD326 functions as a homotypic calcium-independent cell adhesion molecule and is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation. CD326 antigen is an immunotherapeutic target for the treatment of human carcinomas.